SCHEMBL4711991

SCHEMBL4711991

Cc1cccc(/C=C/c2cccc(C)n2)c1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.71
NPC1 O15118 5/20 0.71
KDM4E B2RXH2 4/20 0.71
HPGD P15428 4/20 0.71
RAB9A P51151 4/20 0.71
SMN1; SMN2 Q16637 4/20 0.71
NFKB1 P19838 3/20 0.71
GRM4 Q14833 2/20 0.71
GRM5 P41594 1/20 0.71
NPSR1 Q6W5P4 1/20 0.71
HDAC6 Q9UBN7 1/20 0.71
MEN1 O00255 1/20 0.71
CYP3A4 P08684 1/20 0.71
CYP2D6 P10635 1/20 0.71
CYP2C9 P11712 1/20 0.71
PKM P14618 1/20 0.71
TSHR P16473 1/20 0.71
CYP2C19 P33261 1/20 0.71
THPO P40225 1/20 0.71
KMT2A Q03164 1/20 0.71

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4711993 1.00 ALDH1A1 (0.71) ALDH1A1NPC1KDM4EHPGDRAB9A
SCHEMBL4711823 0.87 ALDH1A1 (0.68) ALDH1A1NPC1KDM4EHPGDRAB9A
SCHEMBL4711824 0.87 ALDH1A1 (0.68) ALDH1A1NPC1KDM4EHPGDRAB9A
SCHEMBL179801 0.83 GRM4 (1.00) ALDH1A1NPC1KDM4EHPGDRAB9A
SCHEMBL29510104 0.83 GRM4 (1.00) ALDH1A1NPC1KDM4EHPGDRAB9A
SCHEMBL350949 0.83 GRM4 (1.00) ALDH1A1NPC1KDM4EHPGDRAB9A
SCHEMBL4710719 0.83 ALDH1A1 (0.67) ALDH1A1NPC1KDM4EHPGDRAB9A
SCHEMBL4710976 0.83 ALDH1A1 (0.67) ALDH1A1NPC1KDM4EHPGDRAB9A
SCHEMBL4710977 0.83 ALDH1A1 (0.67) ALDH1A1NPC1KDM4EHPGDRAB9A
SCHEMBL4710718 0.83 ALDH1A1 (0.67) ALDH1A1NPC1KDM4EHPGDRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0998459-B1 PYRIDINE DERIVATIVES NOVARTIS AG (CH) 2008-04-23 EP disclosed
US-6656957-B1 Marked and selective modulating, especially antagonistic, action at human metabotropic glutamate receptors (mGluRs); treatment of disorders such as epilepsy, cerebral ischemias, especially acute ischemias, spasticity etc. NOVARTIS AG (CH) 2003-12-02 US disclosed